Geron

Geron Corporation has appointed Harout Semerjian as President and CEO effective August 7, 2025, bringing over 30 years of hematology and oncology experience from leadership roles at Novartis, Ipsen, and GlycoMimetics.

Imetelstat, a first-in-class telomerase inhibitor, is advancing to phase 3 trials after demonstrating promising survival benefits in patients with myelofibrosis resistant to JAK inhibitor therapy.

• Vivo Capital has closed the third cycle of its Opportunity Fund with over $740 million in commitments, focusing on preclinical and clinical-stage life sciences companies developing novel therapies. • The fund has previously backed companies that achieved significant milestones, including FDA approvals for treatments targeting COPD, myelodysplastic syndrome, narcolepsy, and Prader-Willi Syndrome. • Several Vivo-backed companies have been acquired by pharmaceutical giants in billion-dollar deals, including RayzeBio (Bristol-Myers Squibb, $4.1B), Chinook Therapeutics (Novartis, $3.2B), and Sierra Oncology (GSK, $1.9B).

New analyses from IMerge Phase 3 trial demonstrate imetelstat's efficacy in lower-risk MDS patients, showing consistent clinical activity regardless of prior treatment history.

Geron Corporation achieved $47.5 million in RYTELO (imetelstat) net product revenue in Q4 2024 and $76.5 million since its commercial launch in June 2024, following FDA approval for lower-risk myelodysplastic syndromes.

The FDA approved Madrigal's Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a significant unmet need in liver disease.

The FDA has approved RYTELO™ (imetelstat) for adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.

MAIA Biotechnology's stock increased by 14% following the FDA's approval of imetelstat, validating telomere targeting as a viable therapeutic approach.